bristol-myers’-stock-decline-in-response-to-weak-guidance-is-a-gift-to-investors
Earnings
0

Bristol Myers’ stock decline in response to weak guidance is a gift to investors

Posted bywamdiness

Boxes of Opdivo from Bristol Myers are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, July 22, 2022.

George Frey | Reuters

Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken.

Source: www.cnbc.com